– UK, York – Tissue Regenix Group (LON: TRX) the regenerative medical devices company, today announced the appointment of Danny Lee to its Board of Directors as CEO effective immediately, succeeding Gareth Jones, who was appointed Interim CEO in August 2019.
Gareth will step down from the Board with immediate effect and plans to remain with the Group until the end of 2020 to effect an orderly handover.
“I am delighted to welcome Danny to the Board of Tissue Regenix as Group CEO. Since joining us in January 2019, Danny has demonstrated exceptional leadership skills and was the stand out candidate from a thorough external recruitment process.”said Interim Chairman, Jonathan Glenn.
He added: “I would also like to thank Gareth, who stepped up on an interim basis to CEO in very difficult circumstances and led the business admirably during this period.”
About Danny Lee
Danny who joined the Group as President of U.S. Operations in January 2019, resides in the United States and has nearly 30 years’ experience in the medical device and biologics industry. Before joining the Group in January 2019, Danny was the Chief Executive Officer for Scaffold Biologics and Aperion Biologics. His previous senior management roles included global marketing for OsteoBiologics and marketing activities for Regeneration Technologies, a leading allograft tissue processor. Danny spent the first ten years of his career in R&D with the U.S. Surgical Corporation. Danny received his B.E.S. degree in Materials Science and Engineering from Johns Hopkins University and his M.S. in Biomedical Engineering from the University of Alabama at Birmingham.
Danny Lee said: “I would like to thank Gareth for his leadership during a transitional period for the company. I am honoured to be selected to lead this company. Throughout my career, I have been passionate about building and growing companies in the regenerative medical space. During my tenure at the Company, I have had the opportunity to appreciate the impact created by our proprietary products and the exceptional capabilities of our team. I look forward to continuing the growth of our company in a dynamic market, identifying additional opportunities to innovate, and taking the decisive actions needed to move our business forward.”
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The Company’s patented decellularisation technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States – ‘Tissue Regenix Wound Care Inc.’, January 2016 saw the establishment of joint venture GBM-V, a multi-tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight’s human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.
For more information: https://www.tissueregenix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.